BioNTech (BNTX) vs Royalty Pharma (RPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Royalty Pharma (RPRX) has outperformed BioNTech (BNTX) over the past year, gaining 57.2% versus a loss of 10.2%. Over five years, RPRX leads with a +47.9% price change compared with -61.5% for BNTX. Royalty Pharma is the larger company by market cap ($32.80 billion vs $23.93 billion), about 1.4 times the size.
Royalty Pharma pays a dividend yielding 1.60%, while BioNTech does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | RPRX |
|---|---|---|
| Share price | $95.25 | $56.76 |
| Market cap | $23.93B | $32.80B |
| 1-day change | -0.50% | +0.57% |
| YTD return | +0.05% | +46.89% |
| 1-year return | -10.19% | +57.23% |
| 5-year return | -61.54% | +47.85% |
| P/E ratio (TTM) | — | 30.19 |
| Forward P/E | — | 9.90 |
| EPS (TTM) | $-7.83 | $1.88 |
| Dividend yield | 0.00% | 1.60% |
| Annual dividend | $0.00 | $0.91 |
| Revenue (latest FY) | — | $2.38B |
| Revenue growth (YoY) | — | +5.06% |
| Net income (latest FY) | — | $770.95M |
| Operating margin | — | 65.58% |
| Net margin | — | 32.42% |
| 52-week high | $124.00 | $64.38 |
| 52-week low | $79.52 | $35.23 |
| Distance from 52-week high | -23.19% | -11.84% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +21.56% | +15.19% |
| Average volume | 1.15M | 2.93M |
| Shares outstanding | 251.20M | 445.28M |
| Employees | 7,807 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RPRX has outperformed BNTX by 67.4 percentage points over the past year.
- Royalty Pharma offers a meaningfully higher dividend yield (1.60% vs 0.00%).
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
BNTX vs RPRX FAQ
Which is bigger, BioNTech or Royalty Pharma?
Royalty Pharma (RPRX) is larger, with a market capitalization of $32.80B compared with $23.93B for BioNTech (BNTX).
Which stock has performed better over the past year, BNTX or RPRX?
RPRX returned +57.23% over the past 12 months, compared with -10.19% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, BioNTech or Royalty Pharma?
Royalty Pharma pays a dividend yielding 1.60%, while BioNTech does not currently pay a regular dividend.
Are BioNTech and Royalty Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioNTech and Biotechnology: Pharmaceutical Preparations for Royalty Pharma.